Endocrine-related adverse conditions induced by tyrosine kinase inhibitors
Author:
Funder
Ministero della Salute
Publisher
Elsevier BV
Subject
Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism
Reference126 articles.
1. Targeting cancer with small molecule kinase inhibitors;Zhang;Nat Rev Cancer,2009
2. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020);Huang;J Hematol Oncol,2020
3. Tyrosine kinase inhibitors: multi-targeted or single-targeted?;Broekman;World J Clin Oncol,2011
4. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma;Rimassa;Cancer Treat Rev,2019
5. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer;Cabanillas;Semin Oncol,2019
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. New Insights of Target Therapy: Effects of Tyrosine Kinase Inhibitors on Male Gonadal Function: A Systematic Review;Clinical Genitourinary Cancer;2024-10
2. Cancer knocks you out by fasting: Cachexia as a consequence of metabolic alterations in cancer;Journal of Cellular Physiology;2024-09-08
3. A disproportionality analysis of sunitinib in the FDA adverse event reporting system (FAERS);Heliyon;2024-09
4. The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function;Clinical Thyroidology®;2024-04-01
5. Tyrosine kinase inhibitor–induced hypothyroidism: mechanism and clinical implications;European Journal of Clinical Pharmacology;2024-03-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3